These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Long-Term Follow-Up of a Pilot Study Using Placenta-Derived Decidua Stromal Cells for Severe Acute Graft-versus-Host Disease. Sadeghi B; Remberger M; Gustafsson B; Winiarski J; Moretti G; Khoein B; Klingspor L; Westgren M; Mattsson J; Ringdén O Biol Blood Marrow Transplant; 2019 Oct; 25(10):1965-1969. PubMed ID: 31173898 [TBL] [Abstract][Full Text] [Related]
11. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Dimopoulos MA; Moreau P; Palumbo A; Joshua D; Pour L; Hájek R; Facon T; Ludwig H; Oriol A; Goldschmidt H; Rosiñol L; Straub J; Suvorov A; Araujo C; Rimashevskaya E; Pika T; Gaidano G; Weisel K; Goranova-Marinova V; Schwarer A; Minuk L; Masszi T; Karamanesht I; Offidani M; Hungria V; Spencer A; Orlowski RZ; Gillenwater HH; Mohamed N; Feng S; Chng WJ; Lancet Oncol; 2016 Jan; 17(1):27-38. PubMed ID: 26671818 [TBL] [Abstract][Full Text] [Related]
12. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate. Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856 [TBL] [Abstract][Full Text] [Related]
13. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma. Steele JM J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972 [TBL] [Abstract][Full Text] [Related]
14. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Berenson JR; Cartmell A; Bessudo A; Lyons RM; Harb W; Tzachanis D; Agajanian R; Boccia R; Coleman M; Moss RA; Rifkin RM; Patel P; Dixon S; Ou Y; Anderl J; Aggarwal S; Berdeja JG Blood; 2016 Jun; 127(26):3360-8. PubMed ID: 27207788 [TBL] [Abstract][Full Text] [Related]
15. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation. Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Locatelli F; Bernardo ME; Bertaina A; Rognoni C; Comoli P; Rovelli A; Pession A; Fagioli F; Favre C; Lanino E; Giorgiani G; Merli P; Pagliara D; Prete A; Zecca M Lancet Oncol; 2017 Aug; 18(8):1126-1136. PubMed ID: 28705454 [TBL] [Abstract][Full Text] [Related]
17. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab. Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915 [TBL] [Abstract][Full Text] [Related]
18. A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-Host Disease by National Institutes of Health Criteria in a Japanese Cohort. Ohwada C; Sakaida E; Igarashi A; Kobayashi T; Doki N; Mori T; Kato J; Koda Y; Kanamori H; Tanaka M; Tachibana T; Fujisawa S; Nakajima Y; Numata A; Toyosaki M; Aoyama Y; Onizuka M; Hagihara M; Koyama S; Kanda Y; Nakasone H; Shimizu H; Kato S; Watanabe R; Shono K; Sakai R; Saito T; Nakaseko C; Okamoto S Biol Blood Marrow Transplant; 2020 Jan; 26(1):162-170. PubMed ID: 31536824 [TBL] [Abstract][Full Text] [Related]
19. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584 [TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Krejci M; Doubek M; Buchler T; Brychtova Y; Vorlicek J; Mayer J Ann Hematol; 2005 Oct; 84(10):681-5. PubMed ID: 16001244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]